Warp Speed veteran Hepburn named EVP of R&D at Panther
Plus: Elicio names Preetam Shah CFO and chief strategy officer, and updates from Halozyme, Newron and Skye
Matthew Hepburn has joined Panther Life Sciences Corp. as EVP of R&D. Panther is developing dissolvable microarray patches for transdermal drug and vaccine delivery. Hepburn’s over three decades of experience in government leading infectious disease and pandemic response R&D included serving as vaccine development lead for Operation Warp Speed during the first Trump administration, vaccine and therapeutics lead in the White House Office Pandemic Preparedness and Response Policy during the Biden administration, and 29 years as infectious disease physician at the U.S. Army.
Elicio Therapeutics Inc. (NASDAQ:ELTX) hired Preetam Shah as its CFO and chief strategy officer. A former investment banker with Barclays and Canaccord Genuity, Shah has held CFO positions at Cidara Therapeutics Inc. (NASDAQ:CDTX) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI); he was also chief business officer at Cidara. Elicio, which is developing a clinical oncology portfolio, reverse-merged with Angion Biomedica Corp. last year...